Methacrylic Acid

Methacrylic Acid

SCHEMBL421101

C=C(C)C(=O)O.c1ccc(SSc2ccccn2)nc1

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 1/20 0.61
EHMT1 Q9H9B1 1/20 0.61
APOBEC3G Q9HC16 1/20 0.61
ALDH1A1 P00352 8/20 0.47
SMN1; SMN2 Q16637 3/20 0.44
HPGD P15428 3/20 0.44
HSD17B10 Q99714 3/20 0.44
KMT2A Q03164 3/20 0.44
MAPT P10636 3/20 0.44
LMNA P02545 2/20 0.43
POLB P06746 1/20 0.43
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
KDM4E B2RXH2 1/20 0.42
ALOX15 P16050 1/20 0.42
NAPRT Q6XQN6 1/20 0.41
P4HTM Q9NXG6 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 2/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL28890025 0.89 EHMT2 (0.71) EHMT2EHMT1APOBEC3GALDH1A1SMN1; SMN2
SCHEMBL16333612 0.88 EHMT2 (0.59) EHMT2EHMT1APOBEC3GALDH1A1SMN1; SMN2
Methacrylic Acid SCHEMBL28950373 0.88 EHMT2 (0.46) EHMT2EHMT1APOBEC3GALDH1A1SMN1; SMN2
Methacrylic Acid SCHEMBL421102 0.86 ALDH1A1 (0.45) EHMT2EHMT1APOBEC3GALDH1A1SMN1; SMN2
Bicarbonate SCHEMBL16975006 0.85 EHMT2 (0.77) EHMT2EHMT1APOBEC3GALDH1A1SMN1; SMN2
SCHEMBL30858718 0.83 EHMT2 (0.53) EHMT2EHMT1APOBEC3GALDH1A1SMN1; SMN2
Methyl Alcohol SCHEMBL28484914 0.82 EHMT2 (0.90) EHMT2EHMT1APOBEC3GALDH1A1SMN1; SMN2
SCHEMBL15255078 0.81 EHMT2 (0.50) EHMT2EHMT1APOBEC3GALDH1A1SMN1; SMN2
Carbamic Acid SCHEMBL16975015 0.81 EHMT2 (0.71) EHMT2EHMT1APOBEC3GALDH1A1SMN1; SMN2
Propionic Acid SCHEMBL28700286 0.80 EHMT2 (0.63) EHMT2EHMT1APOBEC3GALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025226869-A1 GLUCOSE-RESPONSIVE GLUCAGON-MICELLE FOR THE PREVENTION OF HYPOGLYCEMIA AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-10-30 WO claimed
US-20250276000-A1 METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS GENEVANT SCIENCES GMBH (CH) 2025-09-04 US claimed
US-20180221402-A1 METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS ROIVANT SCIENCES LTD. (GB) 2018-08-09 US claimed
US-20180140710-A1 POLYMERS AND POLYMERIC ASSEMBLIES FOR PEPTIDE AND PROTEIN ENCAOSULATION AND RELEASE, AND METHODS THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-05-24 US claimed
EP-3292155-A1 POLYMERS AND POLYMERIC ASSEMBLIES FOR PEPTIDE AND PROTEIN ENCAOSULATION AND RELEASE, AND METHODS THEREOF University of Massachusetts (US) 2018-03-14 EP claimed
CN-107530436-A Methods, compositions and systems for delivering therapeutic and diagnostic agents into cells 菲泽尔克斯公司 2018-01-02 CN claimed
EP-3247328-A1 METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS PhaseRx, Inc. (US) 2017-11-29 EP claimed
WO-2016179189-A1 POLYMERS AND POLYMERIC ASSEMBLIES FOR PEPTIDE AND PROTEIN ENCAOSULATION AND RELEASE, AND METHODS THEREOF UNIVERSITY OF MASSACHUSETTS (US) 2016-11-10 WO claimed
WO-2016118697-A9 METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS PHASERX, INC. (US) 2016-09-29 WO claimed
WO-2016118697-A1 METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS PHASERX, INC. (US) 2016-07-28 WO claimed
US-9220791-B2 Bispecific intracellular delivery vehicles UNIVERSITY OF WASHINGTON (US) 2015-12-29 US claimed
US-20140294752-A1 METHOD FOR NUCLEIC ACID DELIVERY USING HYALURONIC ACID Research & Business Foundation Sungkyunkwan University (KR) 2014-10-02 US claimed
US-20140228516-A1 BISPECIFIC INTRACELLULAR DELIVERY VEHICLES PHASERX, INC. (US) 2014-08-14 US claimed
EP-2620161-A1 Diblock copolymers and polynucleotide complexes thereof for delivery into cells University of Washington (US) 2013-07-31 EP claimed
EP-3247328-B1 METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS GENEVANT SCIENCES GMBH (CH) 2026-01-07 EP disclosed
WO-2025226869-A1 GLUCOSE-RESPONSIVE GLUCAGON-MICELLE FOR THE PREVENTION OF HYPOGLYCEMIA AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-10-30 WO disclosed
US-20250276000-A1 METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS GENEVANT SCIENCES GMBH (CH) 2025-09-04 US disclosed
WO-2009140427-A2 DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS UNIVERSITY OF WASHINGTON (US) 2009-11-19 WO disclosed
WO-2009140432-A2 MICELLES FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS UNIVERSITY OF WASHINGTON (US) 2009-11-19 WO disclosed
WO-2009140429-A2 MICELLIC ASSEMBLIES UNIVERSITY OF WASHINGTON (US) 2009-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250276000-A1 METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS CD63, LIPA, NPC1L1 EHMT2 4251/4885EHMT1 4421/4885APOBEC3G 2367/4885
US-20180140710-A1 POLYMERS AND POLYMERIC ASSEMBLIES FOR PEPTIDE AND PROTEIN ENCAOSULATION AND RELEASE, AND METHODS THEREOF ECPAS, IAPP, SPPL2B EHMT2 3525/4885EHMT1 3519/4885APOBEC3G 4104/4885
US-20140294752-A1 METHOD FOR NUCLEIC ACID DELIVERY USING HYALURONIC ACID CD44, DNASE1, HNRNPH3 EHMT2 2571/4885EHMT1 2304/4885APOBEC3G 633/4885
US-20140228516-A1 BISPECIFIC INTRACELLULAR DELIVERY VEHICLES CD47, LNPK, ACTB EHMT2 4026/4885EHMT1 4334/4885APOBEC3G 2951/4885
US-20180221402-A1 METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS CD63, LIPA, NPC1L1 EHMT2 4251/4885EHMT1 4421/4885APOBEC3G 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.